Mobile

An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon alfa-...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-006803-35

An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon alfa-naïve patients with genotype 1 chronic hepatitis C

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and tolerability of up to four alb-IFN Q4w regimens (1500 μg, 1800 μg, 2100 μg and 2400 μg) plus daily RBV in IFNα-naïve patients with genotype 1 CHC.

Critère d'inclusion

  • CHONIC HEPATITIS C

Liens